Corbus Pharmaceuticals Holdings, Inc.
NASDAQ:CRBPBiotechnology
+$0.14 today
- Market cap
- $50.18M
- Beta
- 2.59
- P/E (TTM)
- -1.3
- EPS (TTM)
- -$6.35
Volume 0.66M
Average 0.42M
Dividends
Corbus Pharmaceuticals Holdings, Inc. dividends
Review the payout history, yield, and how well earnings and cash flow support the dividend.
Dividends
Dividend history, growth & yield
Yield
0.00%
Annual Div/Share
$0.00
Payout Ratio
0.0%
Frequency
—
Shareholder Yield
0.00%
Next Ex-Date
Not announced
Next Payment
—
Analysis
The current indicated dividend yield is 0.00%. The payout ratio is 0.0%, so compare payout growth against earnings coverage.
Competitor dividends
How does Corbus Pharmaceuticals Holdings, Inc. compare as an income stock?
Compare dividend yield, payout ratios, and buybacks with similar companies.
Competitor Dividends
Peer payout, dividend, and buyback comparison
| Company | Market Cap | Dividend Yield | Annual Dividend | Payout Ratio | Buyback Yield |
|---|---|---|---|---|---|
Forte Biosciences, Inc. NASDAQ:FBRX | $1.63B | 0.00% | $0.00 | 0.00% | 0.00% |
Alector, Inc. NASDAQ:ALEC | $378.15M | 0.00% | $0.00 | 0.00% | 0.00% |
PepGen Inc. NASDAQ:PEPG | $301.98M | 0.00% | $0.00 | 0.00% | 0.00% |
Innate Pharma S.A. NASDAQ:IPHA | $154.15M | 0.00% | $0.00 | 0.00% | 0.00% |
Molecular Partners AG NASDAQ:MOLN | $112.71M | 0.00% | $0.00 | 0.00% | 0.00% |
Milestone Pharmaceuticals Inc. NASDAQ:MIST | $64.74M | 0.00% | $0.00 | 0.00% | 0.00% |
Cardiff Oncology, Inc. NASDAQ:CRDF | $56.49M | 0.00% | $0.00 | 0.00% | 0.00% |
Rani Therapeutics Holdings, Inc. NASDAQ:RANI | $34.38M | 0.00% | $0.00 | 0.00% | 0.00% |
Elicio Therapeutics, Inc. NASDAQ:ELTX | $28.60M | 0.00% | $0.00 | 0.00% | 0.00% |
Questions
Dividend questions
Common questions about CRBP's dividend, answered from reported figures.
Does CRBP stock pay dividends?
Corbus Pharmaceuticals Holdings, Inc. (CRBP) currently pays a dividend. The indicated dividend per share is 0.00 USD and the dividend yield is 0.00%.
Is CRBP's dividend covered?
The payout ratio is 0.0%, so compare that against earnings and free cash flow before relying on the dividend.
Continue the stock analysis
Jump to another research area for this company.